Literature DB >> 19913369

Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination.

Tanja Opriessnig1, Abby R Patterson, Darin M Madson, Narinder Pal, Sheela Ramamoorthy, Xiang-Jin Meng, Patrick G Halbur.   

Abstract

The objectives of this study were (1) to compare the efficacy of two different PCV2 vaccination protocols (colostrum-derived immunity versus piglet vaccination) in a conventional PCV2 growing pig challenge model and (2) to evaluate the efficacy of vaccinating piglets with the same vaccine used in the dams. Two different commercially available vaccines (VAC1; VAC2) were used in the same experiment. Seventy-eight piglets born to vaccinated or non-vaccinated sows were divided into 8 groups. A proportion of the pigs with and a proportion of the pigs without passively acquired immunity were vaccinated at 21 days of age. All pigs except negative controls were challenged with PCV2b at 35 days post-vaccination and necropsied at 21 days post-challenge (dpc). The data indicates that both dam vaccination and piglet vaccination had similar efficacies in reducing PCV2 viral loads and antigen levels in the growing pigs. Interestingly, dam vaccination alone did result in significantly (P<0.05) lower anti-PCV2-antibodies levels at challenge in piglets from dams immunized with VAC2 compared to piglets from VAC1 immunized dams. When data obtained from the growing piglets that were vaccinated with VAC1 or VAC2 were compared, antibody levels and reduction of incidence of PCV2-antigen were not different; however, piglets vaccinated with VAC2 had reduced PCV2-DNA genomic copies in serum by 21 dpc. Vaccination of piglets with the same vaccine as was used on their dams did not appear to affect vaccine efficacy as piglets in these groups had anti-PCV2-antibody levels and PCV2 genomic copies similar to the groups where vaccine was administered to the piglets only. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913369     DOI: 10.1016/j.vetmic.2009.09.056

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  25 in total

1.  Induction of humoral immune response in piglets after perinatal or post-weaning immunization against porcine circovirus type-2 or keyhole limpet hemocyanin.

Authors:  Jessica Law; Robert McCorkell; Greg Muench; Katherine Wynne-Edwards; Hermann M Schaetzl; Cristina Solis; Narges Nourozieh; Regula Waeckerlin; Michael Eschbaumer; Shawn Horsman; Markus Czub
Journal:  Can J Vet Res       Date:  2017-01       Impact factor: 1.310

2.  Comparison of four commercial one-dose porcine circovirus type 2 (PCV2) vaccines administered to pigs challenged with PCV2 and porcine reproductive and respiratory syndrome virus at 17 weeks postvaccination to control porcine respiratory disease complex under Korean field conditions.

Authors:  Changhoon Park; Hwi Won Seo; Kiwon Han; Chanhee Chae
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

3.  Studies on porcine circovirus type 2 vaccination of 5-day-old piglets.

Authors:  K C O'Neill; H G Shen; K Lin; M Hemann; N M Beach; X J Meng; P G Halbur; T Opriessnig
Journal:  Clin Vaccine Immunol       Date:  2011-09-21

4.  Effects of an inactivated porcine circovirus type 2 (PCV2) vaccine on PCV2 virus shedding in semen from experimentally infected boars.

Authors:  Hwi Won Seo; Kiwon Han; Duyeol Kim; Yeonsu Oh; Ikjae Kang; Changhoon Park; Hyun Jang; Chanhee Chae
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

5.  A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.

Authors:  T Opriessnig; H G Shen; N Pal; S Ramamoorthy; Y W Huang; K M Lager; N M Beach; P G Halbur; X J Meng
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

6.  Vaccination of dams increases antibody titer and improves growth parameters in finisher pigs subclinically infected with porcine circovirus type 2.

Authors:  J Kurmann; T Sydler; E Brugnera; E Buergi; M Haessig; M Suter; X Sidler
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

7.  A comparative efficacy test of 1 versus 2 doses of CIRCOQ PCV2 subunit vaccine against naturally occurring PCV2-type d in piglets with high maternally derived antibodies (MDAs) on a Vietnamese swine farm.

Authors:  Duy Tien Do; Khanh Doan Vinh Tran; Anh Tuyet Quach; David Lee; Frank Cj Chang; Carol Py Wu; Toan Nguyen Tat; Chanhee Chae
Journal:  Can J Vet Res       Date:  2021-04       Impact factor: 1.310

8.  Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge.

Authors:  Changhoon Park; Jiwoon Jeong; Kyuhyung Choi; Su-Jin Park; Ikjae Kang; Chanhee Chae
Journal:  Can J Vet Res       Date:  2017-07       Impact factor: 1.310

9.  Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein.

Authors:  Hui-Chen Guo; Xiao-Ming Feng; Shi-Qi Sun; Yan-Quan Wei; De-Hui Sun; Xiang-Tao Liu; Zai-Xin Liu; Jian-Xiong Luo; Hong Yin
Journal:  Virol J       Date:  2012-06-12       Impact factor: 4.099

10.  Effectiveness of two intramuscular combined vaccines for the control of Mycoplasma hyopneumoniae and porcine circovirus type 2 in growing pigs: a randomized field trial.

Authors:  Gwenaël Boulbria; Sophie Brilland; Charlotte Teixeira-Costa; Mathieu Brissonnier; Mathieu Charles; Nathalie Capdevielle; Valérie Normand; Franck Bouchet; Pauline Berton; Roman Krejci; Arnaud Lebret
Journal:  Porcine Health Manag       Date:  2021-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.